Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Feb;135(2):325-6.
doi: 10.1007/s00432-008-0459-2. Epub 2008 Sep 30.

Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?

Alberto Ravaioli, Stefania Nicoletti, Emiliano Tamburini, Maximilian Papi
Case Reports

Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?

Alberto Ravaioli et al. J Cancer Res Clin Oncol. 2009 Feb.

Abstract

Numerous studies referring to conventional chemotherapy for aggressive fibromatosis with the use of doxorubicin, cyclophosphamide, vincristin, vinblastine and other drugs have been published. Imatinib mesylate is a recently developed oral anticancer agent designed to selectively inhibit tyrosine kinases implicated in oncogenesis and it seems to represent a promising opportunity (also in first line) in the treatment of patients with advanced disease not candidate to prior surgery.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

    1. Demetri GD, von Mahren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 346:472–480. doi:10.1056/NEJMoa020461 - PubMed
    1. Drucker BJ, Talpaz M, Resta D et al (2001) Efficacy and safety of a specific inhibitor of the BCR-Abl tyrosine kinase in chronic myelogenous leukemia. N Engl J Med 344:1031–1037. doi:10.1056/NEJM200104053441401 - PubMed
    1. Janinis J, Patriki M, Vini L, Aravantinos G et al (2003) The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 14:181–190. doi:10.1093/annonc/mdg064 - PubMed
    1. Mace J, Biermann JS, Sondak V et al (2002) Response to extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373–2379. doi:10.1002/cncr.11029 - PubMed
    1. Wcislo G, Szarlej-Wcislo K, Szczylik C (2007) Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol 133:533–538. doi:10.1007/s00432-007-0198-9 - PMC - PubMed

MeSH terms

LinkOut - more resources